1. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48:124–31. DOI:
10.1002/pbc.21039. PMID:
16937360.
Article
2. Cichocki F. 2021; Impact of Adaptive NK Cells in Donor Lymphocyte Infusions for the Treatment of Hematological Malignancies. Transplant Cell Ther. 27:101–2. DOI:
10.1016/j.jtct.2021.01.012. PMID:
33781543.
Article
4. Vizler C, Nagy T, Kusz E, Glavinas H, Duda E. 2002; Flow cytometric cytotoxicity assay for measuring mammalian and avian NK cell activity. Cytometry. 47:158–62. DOI:
10.1002/cyto.10066. PMID:
11891720.
Article
6. Koh SK, Park J, Kim SE, Lim Y, Phan MT, Kim J, et al. 2022; Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used. Ann Lab Med. 42:638–49. DOI:
10.3343/alm.2022.42.6.638. PMID:
35765872. PMCID:
PMC9277036.
Article
7. Chung HJ, Park CJ, Lim JH, Jang S, Chi HS, Im HJ, et al. 2010; Establishment of a reference interval for natural killer cell activity through flow cytometry and its clinical application in the diagnosis of hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 32:239–47. DOI:
10.1111/j.1751-553X.2009.01177.x. PMID:
19614711.
Article
8. Son BK, Roberts RL, Ank BJ, Stiehm ER. 1996; Effects of anticoagulant, serum, and temperature on the natural killer activity of human peripheral blood mononuclear cells stored overnight. Clin Diagn Lab Immunol. 3:260–4. DOI:
10.1128/cdli.3.3.260-264.1996. PMID:
8705665. PMCID:
PMC170325.
Article